0000000000467639

AUTHOR

Antonino Saporoso

showing 2 related works from this author

Mutation spectrum of NF1 gene in Italian patients with neurofibromatosis type 1 using Ion Torrent PGM™ platform

2017

Neurofibromatosis type 1 (NF1) is caused by mutations of the NF1 gene and is one of the most common human autosomal dominant disorders. The patient shows different signs on the skin and other organs from early childhood. The best known are six or more café au lait spots, axillary or inguinal freckling, increased risk of developing benign nerve sheath tumours and plexiform neurofibromas. Mutation detection is complex, due to the large gene size, the large variety of mutations and the presence of pseudogenes. Using Ion Torrent PGM™ Platform, 73 mutations were identified in 79 NF1 Italian patients, 51% of which turned out to be novel mutations. Pathogenic status of each variant was classifi…

Male0301 basic medicineDNA Mutational Analysismedicine.disease_causeChildGenetics (clinical)Sanger sequencingGeneticsMutationNeurofibromin 1biologyMosaicismCafe-au-Lait SpotsNeurofibromatosis type 1; Legius's syndrome; Next generation sequencingGeneral MedicineMiddle AgedItalyChild PreschoolsymbolsMedical geneticsFemalemedicine.symptomHumanAdultmedicine.medical_specialtyNeurofibromatosis 1AdolescentPseudogeneDNA Mutational Analysi03 medical and health sciencessymbols.namesakeGeneticNext generation sequencingCafé au lait spotSkin AbnormalitieGeneticsmedicineHumansCafe-au-Lait SpotNeurofibromatosisLegius's syndromeInfantSequence Analysis DNAIon semiconductor sequencingmedicine.diseaseNeurofibromin 1030104 developmental biologyMutationSkin Abnormalitiesbiology.proteinNeurofibromatosis type 1European Journal of Medical Genetics
researchProduct

Diagnostic Targeted Resequencing in 349 Patients with Drug-Resistant Pediatric Epilepsies Identifies Causative Mutations in 30 Different Genes

2017

Targeted resequencing gene panels are used in the diagnostic setting to identify gene defects in epilepsy. We performed targeted resequencing using a 30-genes panel and a 95-genes panel in 349 patients with drug-resistant epilepsies beginning in the first years of life. We identified 71 pathogenic variants, 42 of which novel, in 30 genes, corresponding to 20.3% of the probands. In 66% of mutation positive patients seizures onset occurred before age 6 months. The 95-genes panel allowed a genetic diagnosis in 22 (6.3%) patients that would have otherwise been missed using the 30-gene panel. About 50% of mutations were identified in genes coding for sodium and potassium channel components. SCN2…

0301 basic medicineProbandMaleCDKL5Drug Resistancemedicine.disease_causeBioinformaticsEpilepsyAnticonvulsantSTXBP1Age of OnsetChildGenetics (clinical)AlleleMutationepilepsy; next-generation sequencing; gene panel; mutationPhenotypeMagnetic Resonance ImagingSettore MED/39 - Neuropsichiatria Infantile3. Good healthPhenotypeChild PreschoolAnticonvulsantsFemaleSequence AnalysisHumanAdolescentGenotypeGenetic Association StudieBiologyMECP203 medical and health sciencesGeneticgene panelGeneticsmedicineHumansGenetic Predisposition to DiseasePreschoolGeneAllelesGenetic Association StudiesGene Expression ProfilingInfant NewbornComputational BiologyInfantMolecular Sequence AnnotationDNASequence Analysis DNANewbornmedicine.disease030104 developmental biologyepilepsynext-generation sequencingmutation
researchProduct